New research shows marijuana-based treatments could delay the progression of a fatal condition known as Lou Gehrig’s disease, or amyotrophic lateral sclerosis (ALS). The study, published in the...
France’s ministry of health announced Thursday that it has approved Sativex, a cannabis-based mouth spray produced by GW pharmaceutricals. Sativex will be available in France in 2015...
GW Pharmaceuticals has launched their Sativex cannabis extract spray in Italy for use by Multiple Sclerosis (MS) patients. Beware of GW’s creeping monopoly on medical marijauna in...
At the behest of Social Affairs and Health Minister Marisol Touraine, France has modified its Public Health Code to allow for the use of marijuana-based medicines, apparently...
GW Pharmaceuticals plc (GWP), the maker of Sativex and undeniably the original marijuana stock, files for U.S. IPO after recent interest in lesser-known but more hyped U.S. medical...
The French government is considering legalizing Sativex, a marijuana-based nasal or mouth spray for muscle pain, such as people with multiple sclerosis. Sativex would be the first authorized use...
The Irish Department of Health says it hopes to bring forward legislative proposals this year, or in early 2013, enabling cannabis-based medicines to be prescribed in Ireland.
